Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Spirometric classifications of COPD severity as predictive markers for clinical outcomes: the HUNT Study

View ORCID ProfileLaxmi Bhatta, Linda Leivseth, Xiao-Mei Mai, Anne Hildur Henriksen, David Carslake, Yue Chen, Pablo Martinez-Camblor, Arnulf Langhammer, Ben Michael Brumpton
doi: https://doi.org/10.1101/2020.11.03.20221432
Laxmi Bhatta
1Department of Public Health and Nursing, NTNU Norwegian University of Science and Technology, Trondheim, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Laxmi Bhatta
  • For correspondence: laxmi.bhatta@ntnu.no
Linda Leivseth
2Centre for Clinical Documentation and Evaluation (SKDE), Northern Norway Regional Health Authority, Tromsø, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiao-Mei Mai
1Department of Public Health and Nursing, NTNU Norwegian University of Science and Technology, Trondheim, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Hildur Henriksen
3Department of Circulation and Medical Imaging, NTNU Norwegian University of Science and Technology, Trondheim, Norway
4Clinic of Thoracic and Occupational Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Carslake
5MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK
6Population Health Sciences, University of Bristol, Bristol, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yue Chen
7School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pablo Martinez-Camblor
8Biomedical Data Science Department, Geisel School of Medicine at Dartmouth, Hanover, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arnulf Langhammer
9HUNT Research Centre, NTNU Norwegian University of Science and Technology, Levanger, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ben Michael Brumpton
4Clinic of Thoracic and Occupational Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
5MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK
10K.G. Jebsen Center for Genetic Epidemiology, NTNU Norwegian University of Science and Technology, Trondheim, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Rationale GOLD grades based on percent-predicted FEV1 poorly predicts mortality. Studies have recommended alternative expressions of FEV1 for the classification of COPD severity and they warrant investigation.

Objective To compare the predictive abilities of ppFEV1 (ppFEV1 quartiles, GOLD grades, ATS/ERS grades), FEV1 z-score (FEV1 z-score quartiles, FEV1 z-score grades), FEV1.Ht-2 (FEV1.Ht-2 quartiles, FEV1.Ht-2 grades), FEV1.Ht-3 (FEV1.Ht-3 quartiles), and FEV1Q (FEV1Q quartiles) to predict clinical outcomes.

Methods People aged ≥40 years with COPD (n=890) who participated in the HUNT Study (1995-1997) were followed for 5 years (short-term) and up to 20.4 years (long-term). Survival analysis and time-dependent area under curve (AUC) were used to compare the predictive abilities. A regression tree approach was applied to obtain optimal cut-offs of different expressions of FEV1. The UK Biobank (n=6495) was used as a replication cohort with a 5-year follow-up.

Results As a continuous variable, FEV1Q had the highest AUCs for all-cause mortality (short-term 70.2, long-term 68.3), respiratory mortality (short-term 68.4, long-term 67.7), cardiovascular mortality (short-term 63.1, long-term 62.3), COPD hospitalization (short-term 71.3, long-term 70.9), and pneumonia hospitalization (short-term 67.8, long-term 66.6), followed by FEV1.Ht-2 or FEV1.Ht-3. Generally, similar results were observed for FEV1Q quartiles. The optimal cut-offs of FEV1Q had higher AUCs compared to GOLD grades for predicting short-term and long-term clinical outcomes. Similar results were found in UK Biobank.

Conclusions FEV1Q best predicted the clinical outcomes and could improve the classification of COPD severity.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by ExtraStiftelsen Helse og Rehabilitering and Landsforeningen for hjerte-og-lungesyke (the Norwegian Extra Foundation for Health and Rehabilitation and the Norwegian Heart and Lung Patient Organization) (project number 2016/FO79031) and the liason committee of the Central Norway Regional Health Authority and NTNU (Norwegian University of Science and Technology).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethical approval was obtained from the Regional Committees for Medical and Health Research Ethics (2015/1461/REK midt). All participants gave informed written consent.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data are available upon reasonable request and with permission of HUNT Research Centre.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted November 05, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Spirometric classifications of COPD severity as predictive markers for clinical outcomes: the HUNT Study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Spirometric classifications of COPD severity as predictive markers for clinical outcomes: the HUNT Study
Laxmi Bhatta, Linda Leivseth, Xiao-Mei Mai, Anne Hildur Henriksen, David Carslake, Yue Chen, Pablo Martinez-Camblor, Arnulf Langhammer, Ben Michael Brumpton
medRxiv 2020.11.03.20221432; doi: https://doi.org/10.1101/2020.11.03.20221432
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Spirometric classifications of COPD severity as predictive markers for clinical outcomes: the HUNT Study
Laxmi Bhatta, Linda Leivseth, Xiao-Mei Mai, Anne Hildur Henriksen, David Carslake, Yue Chen, Pablo Martinez-Camblor, Arnulf Langhammer, Ben Michael Brumpton
medRxiv 2020.11.03.20221432; doi: https://doi.org/10.1101/2020.11.03.20221432

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Respiratory Medicine
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (44)
  • Cardiovascular Medicine (408)
  • Dentistry and Oral Medicine (67)
  • Dermatology (47)
  • Emergency Medicine (141)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4810)
  • Forensic Medicine (3)
  • Gastroenterology (177)
  • Genetic and Genomic Medicine (671)
  • Geriatric Medicine (70)
  • Health Economics (187)
  • Health Informatics (621)
  • Health Policy (314)
  • Health Systems and Quality Improvement (200)
  • Hematology (85)
  • HIV/AIDS (155)
  • Infectious Diseases (except HIV/AIDS) (5280)
  • Intensive Care and Critical Care Medicine (326)
  • Medical Education (91)
  • Medical Ethics (24)
  • Nephrology (73)
  • Neurology (677)
  • Nursing (41)
  • Nutrition (110)
  • Obstetrics and Gynecology (124)
  • Occupational and Environmental Health (203)
  • Oncology (438)
  • Ophthalmology (138)
  • Orthopedics (36)
  • Otolaryngology (88)
  • Pain Medicine (35)
  • Palliative Medicine (15)
  • Pathology (127)
  • Pediatrics (193)
  • Pharmacology and Therapeutics (129)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (768)
  • Public and Global Health (1798)
  • Radiology and Imaging (321)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (68)
  • Sports Medicine (61)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (28)
  • Urology (37)